The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Aug. 04, 2015

Filed:

Sep. 04, 2012
Applicants:

Leif Andersson, Uppsala, SE;

Gerli Rosengren Pielberg, Uppsala, SE;

Anna Olegovna Golovko, Uppsala, SE;

Kjell Robert Johan Lennartsson, Heby, SE;

Carl-henrik Heldin, Uppsala, SE;

Inventors:

Leif Andersson, Uppsala, SE;

Gerli Rosengren Pielberg, Uppsala, SE;

Anna Olegovna Golovko, Uppsala, SE;

Kjell Robert Johan Lennartsson, Heby, SE;

Carl-Henrik Heldin, Uppsala, SE;

Assignee:

Biocistronix AB, Uppsala, SE;

Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
C12N 15/11 (2006.01); C12Q 1/68 (2006.01);
U.S. Cl.
CPC ...
C12Q 1/6881 (2013.01); C12Q 1/6886 (2013.01); C12Q 2600/124 (2013.01); C12Q 2600/136 (2013.01); C12Q 2600/156 (2013.01); C12Q 2600/158 (2013.01); C12Q 2600/172 (2013.01);
Abstract

This document relates to methods and materials for determining whether or not a horse contains a Grey allele. For example, diagnostic methods such as nucleic acid-based detection methods and materials such as nucleic acid probes and primer pairs that can be used to determine whether or not a horse contains a duplication in intron 6 of STX17 nucleic acid are provided. This document also relates to methods and materials for treating a mammal having or being likely to develop cancer (e.g., benign, malignant, or metastatic cancer). For example, methods and materials for treating cancer in a mammal by administering an agent having the ability to reduce expression of an STX17 polypeptide and/or an NR4A polypeptide (e.g., an NR4A1, NR4A2, or NR4A3 polypeptide) in the mammal are provided.


Find Patent Forward Citations

Loading…